Ionis Pharmaceuticals, Inc. Common Stock
IONSNasdaqCIK 874015Healthcare / Drug Manufacturersfiscal year ends December70 quarters since 2009
Latest quarter Q3 FY2026, filed November 9, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.
Share price
Daily candlesticks from November 18, 2024 to November 13, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.
The last 16 quarters
Q4 FY2022 to Q3 FY2026, through the filing of November 9, 2026.
Net income losses drawn in red.
Operating cash flow less capital expenditures; negative quarters in red.
Positions at each quarter end, as filed; short-term investments are not included.
Income statement
Last eight quarters, newest first, through Q3 FY2026 filed November 9, 2026.
| Millions of dollars | Q3 FY2026ended Sep 30, 2026filed Nov 9, 2026 | Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026 | Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026 | Q4 FY2025ended Dec 31, 2025filed Jul 30, 2025 | Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025 | Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025 | Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025 | Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 243 | 268 | 246 | 203 | 157 | 452 | 132 | 227 | +54.9% |
| Cost of revenue | 3 | 3 | 3 | 8 | 2 | 4 | 1 | 4 | +42.1% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — | — | — |
| Selling, general and administrative | 154 | 150 | 150 | 130 | 97 | 91 | 76 | 88 | +59.3% |
| Operating income | (131) | (102) | (117) | (214) | (160) | 140 | (147) | (111) | +18.4% |
| Other income (expense) | 0 | 1 | 0 | (16) | 0 | 0 | 0 | 0 | −23.7% |
| Pretax income | (110) | (113) | (92) | (228) | (128) | 124 | (147) | (107) | +14.2% |
| Income tax | 0 | 1 | 0 | 1 | 0 | 0 | 0 | (3) | −166.2% |
| Net income | (110) | (115) | (93) | (229) | (129) | 124 | (147) | (104) | +14.5% |
| Diluted EPS ($) | (0.66) | (0.69) | (0.56) | (1.41) | (0.80) | 0.70 | (0.93) | (0.66) | +17.5% |
| Diluted shares (millions) | 166 | 165 | 165 | — | 160 | 182 | 159 | — | — |
Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.
Balance sheet
Last eight quarters, newest first, through Q3 FY2026 filed November 9, 2026.
| Millions of dollars | Q3 FY2026ended Sep 30, 2026filed Nov 9, 2026 | Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026 | Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026 | Q4 FY2025ended Dec 31, 2025filed Jul 30, 2025 | Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025 | Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025 | Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025 | Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 296 | 350 | 173 | 372 | 338 | 297 | 264 | 242 | −12.4% |
| Short-term investments | 1,588 | 1,705 | 1,746 | 2,305 | 1,902 | 1,993 | 1,881 | 2,056 | −16.5% |
| Total current assets | 2,362 | 2,491 | 2,937 | 2,991 | 2,519 | 2,577 | 2,419 | 2,620 | −6.3% |
| Total assets | 2,913 | 2,995 | 3,450 | 3,524 | 3,033 | 2,985 | 2,813 | 3,004 | −4.0% |
| Total current liabilities | 435 | 316 | 717 | 782 | 903 | 897 | 250 | 309 | −51.8% |
| Long-term debt | — | — | — | 1,328 | — | — | — | 1,202 | — |
| Total debt | — | — | — | 1,812 | — | — | — | 1,253 | — |
| Total liabilities | 2,519 | 2,555 | 2,959 | 3,035 | 2,415 | 2,353 | 2,337 | 2,415 | +4.3% |
| Stockholders’ equity | 394 | 440 | 491 | 489 | 618 | 632 | 476 | 588 | −36.3% |
| Shares outstanding (millions) | 167 | 166 | 165 | 165 | 162 | 159 | 159 | 159 | — |
Positions at each period end. Long-term debt is the line the filer tags, with or without its current portion. Total debt is one definition across filers, built from filed lines: long-term debt with its current portion plus short-term borrowings, finance leases where the filer folds them into its debt line, operating leases never; it is blank where the tags do not add up to it. Italic figures are derived.
Cash flow statement
Last eight quarters, newest first, through Q3 FY2026 filed November 9, 2026.
| Millions of dollars | Q3 FY2026ended Sep 30, 2026filed Nov 9, 2026 | Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026 | Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026 | Q4 FY2025ended Dec 31, 2025filed Jul 30, 2025 | Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025 | Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025 | Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025 | Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | (179) | 566 | (793) | (138) | (131) | 151 | (151) | (116) | −36.5% |
| Capital expenditures | 13 | 16 | 22 | 21 | 5 | 12 | 13 | 25 | +141.2% |
| Free cash flow (CFO − capex) | (192) | 549 | (815) | (159) | (137) | 139 | (163) | (142) | −40.5% |
| Depreciation and amortization | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | +50.7% |
| Share repurchases | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — |
10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.
Annual statements
Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.
Income statement
| Millions of dollars | FY2025ended Dec 31, 2025filed Jul 30, 2025 | FY2024ended Dec 31, 2024filed Feb 19, 2025 | FY2023ended Dec 31, 2023filed Feb 21, 2024 | FY2022ended Dec 31, 2022filed Feb 22, 2023 | FY2021ended Dec 31, 2021filed Feb 25, 2022 | FY2020ended Dec 31, 2020filed Feb 24, 2021 | FY2019ended Dec 31, 2019filed Mar 2, 2020 | FY2018ended Dec 31, 2018filed Mar 1, 2019 | FY2017ended Dec 31, 2017filed Feb 28, 2018 | FY2016ended Dec 31, 2016filed Mar 1, 2017 | FY2015ended Dec 31, 2015filed Feb 26, 2016 | FY2014ended Dec 31, 2014filed Mar 2, 2015 | FY2013ended Dec 31, 2013filed Mar 3, 2014 | FY2012ended Dec 31, 2012filed Feb 28, 2013 | FY2011ended Dec 31, 2011filed Feb 29, 2012 | FY2010ended Dec 31, 2010filed Mar 1, 2011 | FY2009ended Dec 31, 2009filed Aug 9, 2010 | FY2008ended Dec 31, 2008filed Aug 9, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 944 | 705 | 788 | 587 | 810 | 729 | 1,123 | 600 | 514 | 373 | 284 | 214 | 147 | 102 | 99 | 108 | 122 | 107 |
| Cost of revenue | 16 | 11 | 9 | 14 | 11 | 12 | 4 | 2 | 0 | 0 | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research and development | 916 | 902 | 900 | — | 638 | 531 | 462 | 412 | 373 | 340 | 320 | 239 | 174 | 155 | 153 | 145 | 135 | 106 |
| Selling, general and administrative | 394 | 267 | 233 | 150 | 186 | 354 | 287 | 245 | 108 | 49 | 37 | 20 | 15 | 13 | 13 | 12 | 15 | 14 |
| Operating income | (382) | (475) | (354) | (410) | (30) | (172) | 366 | (61) | 31 | (20) | (76) | (48) | (52) | (69) | (71) | (48) | (28) | (13) |
| Other income (expense) | (15) | 1 | 14 | (7) | (10) | 0 | (1) | 0 | (4) | 0 | — | — | — | — | — | — | — | — |
| Pretax income | (380) | (460) | (334) | (258) | (29) | (135) | 339 | (76) | (17) | (57) | (88) | (54) | (67) | (75) | (85) | (61) | (32) | — |
| Income tax | 2 | (6) | 32 | 12 | (1) | 345 | 52 | (291) | (6) | 3 | 0 | (15) | (6) | (9) | 0 | 0 | 3 | — |
| Net income | (381) | (454) | (366) | (270) | (29) | (444) | 278 | 274 | 0 | (60) | (88) | (39) | (61) | — | — | (61) | 155 | (18) |
| Diluted EPS ($) | (2.38) | (3.04) | (2.56) | (1.90) | (0.20) | (3.18) | 1.90 | 2.07 | 0.15 | (0.50) | (0.74) | — | — | — | (0.85) | (0.62) | 1.58 | (0.19) |
| Diluted shares (millions) | 160 | 150 | 143 | 142 | 141 | 140 | 153 | 134 | 126 | 121 | 120 | — | 111 | 101 | 100 | 99 | 98 | 95 |
Balance sheet
| Millions of dollars | FY2025ended Dec 31, 2025filed Jul 30, 2025 | FY2024ended Dec 31, 2024filed Feb 19, 2025 | FY2023ended Dec 31, 2023filed Feb 21, 2024 | FY2022ended Dec 31, 2022filed Feb 22, 2023 | FY2021ended Dec 31, 2021filed Feb 25, 2022 | FY2020ended Dec 31, 2020filed Feb 24, 2021 | FY2019ended Dec 31, 2019filed Mar 2, 2020 | FY2018ended Dec 31, 2018filed Mar 1, 2019 | FY2017ended Dec 31, 2017filed Feb 28, 2018 | FY2016ended Dec 31, 2016filed Mar 1, 2017 | FY2015ended Dec 31, 2015filed Feb 26, 2016 | FY2014ended Dec 31, 2014filed Mar 2, 2015 | FY2013ended Dec 31, 2013filed Mar 3, 2014 | FY2012ended Dec 31, 2012filed Feb 28, 2013 | FY2011ended Dec 31, 2011filed Feb 29, 2012 | FY2010ended Dec 31, 2010filed Mar 1, 2011 | FY2009ended Dec 31, 2009filed Aug 9, 2010 | FY2008ended Dec 31, 2008filed Aug 9, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 372 | 242 | 399 | 276 | 869 | 398 | 683 | 279 | 130 | 85 | 129 | 143 | 160 | 124 | 65 | 70 | 105 | 224 |
| Short-term investments | 2,305 | 2,056 | 1,932 | 1,710 | 1,246 | 1,495 | 1,816 | 1,805 | 893 | 581 | 650 | 586 | 497 | 250 | 278 | 402 | — | — |
| Total current assets | 2,991 | 2,620 | 2,642 | 2,203 | 2,345 | 2,131 | 2,721 | 2,208 | 1,169 | 798 | 837 | 837 | 736 | 423 | 360 | 483 | 596 | — |
| Total assets | 3,524 | 3,004 | 2,990 | 2,534 | 2,612 | 2,390 | 3,233 | 2,668 | 1,323 | 912 | 948 | 956 | 847 | 546 | 485 | 550 | 657 | — |
| Total current liabilities | 782 | 309 | 448 | 312 | 241 | 599 | 273 | 280 | 244 | 134 | 149 | 115 | 98 | 74 | 76 | 106 | 111 | — |
| Long-term debt | 1,328 | 1,202 | 1,241 | 1,176 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total debt | 1,812 | 1,253 | 1,308 | 1,194 | — | 840 | 788 | — | — | — | — | — | — | — | 149 | 154 | 16 | — |
| Total liabilities | 3,035 | 2,415 | 2,603 | 1,961 | 1,840 | 1,646 | 1,549 | 1,481 | 957 | 813 | 747 | 698 | 469 | 363 | 313 | 306 | 355 | — |
| Stockholders’ equity | 489 | 588 | 387 | 573 | 772 | 743 | 1,471 | 1,048 | 281 | 100 | 201 | 258 | 378 | 183 | 171 | 245 | 292 | — |
| Shares outstanding (millions) | 165 | 159 | 146 | 143 | 142 | 141 | 139 | 138 | 125 | 124 | 121 | 119 | 117 | 102 | 100 | 100 | — | — |
Cash flow statement
| Millions of dollars | FY2025ended Dec 31, 2025filed Jul 30, 2025 | FY2024ended Dec 31, 2024filed Feb 19, 2025 | FY2023ended Dec 31, 2023filed Feb 21, 2024 | FY2022ended Dec 31, 2022filed Feb 22, 2023 | FY2021ended Dec 31, 2021filed Feb 25, 2022 | FY2020ended Dec 31, 2020filed Feb 24, 2021 | FY2019ended Dec 31, 2019filed Mar 2, 2020 | FY2018ended Dec 31, 2018filed Mar 1, 2019 | FY2017ended Dec 31, 2017filed Feb 28, 2018 | FY2016ended Dec 31, 2016filed Mar 1, 2017 | FY2015ended Dec 31, 2015filed Feb 26, 2016 | FY2014ended Dec 31, 2014filed Mar 2, 2015 | FY2013ended Dec 31, 2013filed Mar 3, 2014 | FY2012ended Dec 31, 2012filed Feb 28, 2013 | FY2011ended Dec 31, 2011filed Feb 29, 2012 | FY2010ended Dec 31, 2010filed Mar 1, 2011 | FY2009ended Dec 31, 2009filed Aug 9, 2010 | FY2008ended Dec 31, 2008filed Aug 9, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | (269) | (501) | (308) | (274) | 31 | 36 | 346 | 603 | 174 | (112) | 21 | — | — | — | (115) | (64) | (108) | 212 |
| Capital expenditures | 51 | 45 | 24 | 16 | 12 | 35 | 31 | 14 | 35 | 7 | 8 | 8 | 2 | 1 | 10 | 13 | 13 | 14 |
| Free cash flow (CFO − capex) | (320) | (546) | (331) | (290) | 19 | 1 | 315 | 589 | 139 | (119) | 13 | — | — | — | (125) | (77) | (122) | 198 |
| Depreciation and amortization | 12 | 12 | 13 | 17 | 18 | 15 | 14 | 13 | 8 | 9 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | 0 | 0 | 91 | 34 | 0 | 0 | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Insider activity
Form 4 filings by officers, directors and 10% owners, November 16, 2024 to November 16, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.
The last 25 transactions
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Hayden Michael R | Director | open-market buyindirect | 5,000 | $29.64 | $148K | 27,000 | Nov 13, 2026 |
| Oct 16, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | open-market sale | 1,357 | $43.54 | $59K | 17,811 | Oct 19, 2026 |
| Oct 16, 2026 | Swayze Eric | EVP Research | open-market saleindirect | 53 | $43.54 | $2K | 390 | Oct 19, 2026 |
| Oct 15, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | option exercise | 2,820 | $0.00 | — | 19,168 | Oct 19, 2026 |
| Oct 15, 2026 | Swayze Eric | EVP Research | option exerciseindirect | 125 | $0.00 | — | 443 | Oct 19, 2026 |
| Aug 31, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | other | 110 | $51.31 | $6K | 60,128 | Sep 2, 2026 |
| Aug 31, 2026 | O'Neil Patrick R. | EVP CLO & General Counsel | other | 63 | $51.31 | $3K | 59,205 | Sep 2, 2026 |
| Aug 31, 2026 | Monia Brett P | Chief Executive Officer, Director | other | 98 | $51.31 | $5K | 242,760 | Sep 2, 2026 |
| Aug 31, 2026 | Birchler Brian | EVP, Corp and Development Ops | other | 58 | $51.31 | $3K | 102,883 | Sep 2, 2026 |
| Jul 31, 2026 | Hayden Michael R | Director | open-market buyindirect | 5,000 | $51.60 | $258K | 24,000 | Jul 31, 2026 |
| Jul 30, 2026 | Hayden Michael R | Director | open-market buyindirect | 15,000 | $53.38 | $801K | 19,000 | Jul 31, 2026 |
| Jul 15, 2026 | Herman Joan E | Director | option exercise | 5,220 | $0.00 | — | 51,306 | Jul 17, 2026 |
| Jul 15, 2026 | Berthelsen Spencer R | Director | option exercise | 5,220 | $0.00 | — | 161,233 | Jul 17, 2026 |
| Jul 7, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | open-market sale10b5-1 | 5,536 | $83.58 | $463K | 75,018 | Jul 9, 2026 |
| Jul 7, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | otherindirect | 15,000 | $0.00 | — | 15,000 | Jul 9, 2026 |
| Jul 7, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | open-market sale10b5-1indirect | 15,000 | $85.46 | $1M | 0 | Jul 9, 2026 |
| Jul 7, 2026 | Diaz Allene M. | Director | option exercise | 10,111 | $47.11 | $476K | 13,922 | Jul 9, 2026 |
| Jul 7, 2026 | Diaz Allene M. | Director | open-market sale10b5-1 | 10,111 | $85.42 | $864K | 3,811 | Jul 9, 2026 |
| Jul 7, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | open-market sale10b5-1 | 362 | $84.30 | $31K | 22,096 | Jul 9, 2026 |
| Jul 1, 2026 | Klein Joseph III | Director | option exercise | 11,518 | $39.94 | $460K | 22,532 | Jul 6, 2026 |
| Jul 1, 2026 | Klein Joseph III | Director | open-market sale10b5-1 | 99 | $79.45 | $8K | 22,433 | Jul 6, 2026 |
| Jul 1, 2026 | Klein Joseph III | Director | open-market sale10b5-1 | 11,419 | $79.04 | $903K | 11,014 | Jul 6, 2026 |
| Jun 26, 2026 | Baroldi Joseph | EVP, Chief Business Officer | option exerciseindirect | 3,866 | $56.78 | $220K | 8,535 | Jun 30, 2026 |
| Jun 26, 2026 | Baroldi Joseph | EVP, Chief Business Officer | option exerciseindirect | 1,769 | $32.60 | $58K | 10,304 | Jun 30, 2026 |
| Jun 26, 2026 | Baroldi Joseph | EVP, Chief Business Officer | open-market sale10b5-1indirect | 5,635 | $80.16 | $452K | 4,669 | Jun 30, 2026 |
Full insider history for Ionis Pharmaceuticals, Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.
Tracked funds holding it
1 of the tracked managers held IONS in their latest 13F filing, through November 12, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded IONS by quarter.
| Fund | Manager | Quarter | Value | Shares | Weight | Move |
|---|---|---|---|---|---|---|
| Renaissance Technologies | Peter Brown | Q3 2026 | $16M | 354,214 | 0.02% | trimmed −36.7% |
Sources
Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.
- Filer
- IONIS PHARMACEUTICALS, INC., CIK 874015 on EDGAR
- Extract generated
- November 16, 2026
- Withheld
- 5 line-years whose four quarters do not sum to the filed year: rnd FY2013, net income FY2016, operating income FY2016, revenue FY2016, net income FY2019
- Repaired
- 1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: pretax income FY2021
XBRL concepts behind each line
Income statement
RevenueFromContractWithCustomerExcludingAssessedTax, RevenuesCostOfGoodsAndServicesSoldResearchAndDevelopmentExpenseGeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpenseOperatingIncomeLossOtherNonoperatingIncomeExpenseIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsIncomeTaxExpenseBenefitNetIncomeLossEarningsPerShareDilutedWeightedAverageNumberOfDilutedSharesOutstandingBalance sheet
CashAndCashEquivalentsAtCarryingValueAvailableForSaleSecuritiesDebtSecuritiesCurrent, ShortTermInvestmentsAssetsCurrentAssetsLiabilitiesCurrentLongTermDebtNoncurrentLongTermDebt, with finance leasesLiabilitiesStockholdersEquitydei:EntityCommonStockSharesOutstandingCash flow statement
NetCashProvidedByUsedInOperatingActivitiesPaymentsToAcquirePropertyPlantAndEquipmentPaymentsForRepurchaseOfCommonStockThe data
The statements on this page as files, generated November 16, 2026.
- JSON file
/data/financials/IONS.json